

Narcolepsy Treatment Market to Reach USD 8,718.3 Million by 2034 With A 5.1% Of CAGR, driven by Rising Sleep Disorders

Global Narcolepsy Treatment Market to Grow at 5.1% CAGR, Reaching USD 8,718.3 Million by 2034. Key Drivers Include Advanced Drugs, Devices, & Growing Awareness.

NEWARK, DE, UNITED STATES, January 14, 2025 /EINPresswire.com/ -- The global [narcolepsy treatment market](#) is poised for robust growth, projected to reach USD 5,301.6 million in 2024 and expand at a 5.1% CAGR to reach USD 8,718.3 million by 2034. Factors such as the increasing prevalence of sleep disorders, obesity, and mental health issues contribute significantly to market expansion. Advancements in pharmaceuticals like Modafinil, Sodium Oxybate, and Armodafinil, alongside cutting-edge devices such as CPAP, BPAP, and APAP, have enhanced treatment accessibility. Emerging diagnostic tools and rising treatment-seeking populations are further fueling growth.



Narcolepsy Treatment Market

A Full Report Analysis - <https://www.futuremarketinsights.com/reports/narcolepsy-treatment-market>

Growth Drivers

Increasing Prevalence of Contributing Conditions: The rising incidence of obesity, sleep disorders, and mental health issues is contributing to the growing prevalence of narcolepsy, thereby driving demand for effective treatments.

Diverse Treatment Options: The market includes various medications such as:

Modafinil

Sodium Oxybate

Armodafinil

Other emerging drugs aimed at managing symptoms.

Additionally, devices like CPAP (Continuous Positive Airway Pressure), BPAP (Bilevel Positive Airway Pressure), and APAP (Automatic Positive Airway Pressure) are increasingly being adopted for treatment.

Advancements in Diagnostic Tools: The development of new diagnostic techniques is expanding the population seeking treatment for narcolepsy, as better diagnosis leads to increased awareness and treatment adoption.

Education and Awareness Campaigns: Programs aimed at educating healthcare professionals and the general public about sleep disorders have significantly contributed to the growing recognition of narcolepsy and its treatment options.

What new drugs are expected to dominate the narcolepsy treatment market?

The narcolepsy treatment market is expected to see significant developments with the introduction of several new drugs that are likely to dominate the market in the coming years. Here are some key drugs and therapies anticipated to make an impact:

Key Emerging Drugs


Pitolisant:

Mechanism: A selective histamine H3-receptor inverse agonist that promotes wakefulness.

Approval Status: Recently approved in Europe and the FDA for treating excessive daytime sleepiness (EDS) associated with narcolepsy.

Benefits: It has shown effectiveness in managing both EDS and cataplexy, with a favorable safety profile.

Solriamfetol (Sunosi):



Mechanism: A dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI).

Usage: Approved for improving wakefulness in adults with EDS due to narcolepsy or obstructive sleep apnea.

Market Position: Expected to gain traction due to its efficacy in enhancing alertness.

Sodium Oxybate (Lumryz):

Mechanism: Regulates sleep patterns and reduces cataplexy incidents.

Recent Developments: The FDA approved Lumryz, an extended-release formulation of sodium oxybate, for treating cataplexy and EDS in narcolepsy patients aged 7 and older.

TAK-861:

Type: An oral orexin receptor agonist under development by Takeda Pharmaceuticals.

Clinical Status: Positive Phase IIb trial results have led to plans for Phase III trials, targeting narcolepsy type 1.

Orexin-Based Therapies:

Research is ongoing into nonpeptide orexin receptor agonists, which may provide new treatment options by addressing the underlying hypocretin deficiency seen in narcolepsy.

Key Drivers of Market Growth

Several factors are driving the narcolepsy treatment market's expansion. Rising awareness through educational campaigns has spurred early diagnosis and treatment adoption. Technological advancements in diagnostic tools and improved therapeutic options are enabling better patient outcomes. However, the presence of side effects associated with current medications presents both a challenge and an opportunity for innovation within the market. Additionally, the growing prevalence of comorbid conditions, such as obesity and depression, necessitates comprehensive treatment solutions, further supporting market demand.

Component Insights and Challenges Facing the Market

Medications such as Modafinil and Sodium Oxybate dominate the market, while advanced respiratory devices like CPAP and APAP are gaining traction among patients. However, side effects linked to drugs remain a challenge, prompting the development of safer alternatives. Limited accessibility in developing regions and high treatment costs may hinder market penetration. Nonetheless, growing investments in research and development, coupled with initiatives to improve healthcare infrastructure, are expected to address these barriers.

Regional Insights and Key Takeaways

North America currently leads the narcolepsy treatment market due to high awareness, advanced healthcare infrastructure, and substantial R&D investments. Europe and the Asia-Pacific region are also witnessing significant growth, driven by increasing awareness and healthcare investments. Key takeaways include the need for innovation in drug formulations and the importance of public education campaigns. As diagnostic techniques advance and treatment options evolve, the global narcolepsy treatment market is poised for continued growth, meeting the needs of a growing patient base.

Competitive Landscape of the Narcolepsy Treatment Industry

Market players are heavily focused on research and development to introduce innovative drugs and treatments, aiming to secure a competitive edge. Companies in the narcolepsy treatment sector are positioned at different stages of drug development.

Some organizations are initiating investigations into novel lead molecules, while others are progressing through clinical trials, moving from Phase 2 to Phase 3 evaluations. Meanwhile, a few companies have completed clinical trials and are preparing for product launches following FDA approvals. This dynamic and diverse development pipeline is expected to drive positive growth in the market over the coming years.

Recent Developments in the Narcolepsy Treatment Market:

October 2024: Avadel Pharmaceuticals Plc received FDA approval for LUMRYZ, an extended-release sodium oxybate oral suspension. LUMRYZ is designed for patients aged seven years and older to treat cataplexy and excessive daytime sleepiness (EDS).

April 2024: Harmony Biosciences Holdings, Inc. initiated a Phase 3 global registrational trial for the TEMPO study. This trial evaluates the safety and efficacy of Pitolisant, a treatment for EDS and behavioral symptoms in Prader-Willi syndrome (PWS) patients aged six years and older.

February 2024: Takeda announced plans to begin a Phase 3 clinical trial to assess TAK-861, an oral orexin receptor 2 agonist, for treating narcolepsy type 1 patients.

These advancements reflect the industry's commitment to addressing unmet needs in narcolepsy treatment through innovative approaches and strategic developments.

Key Players of the Narcolepsy Treatment Industry

ResMed Inc.

Koninklijke Philips N.V.

Merck & Co. Inc.

Drive DeVilbiss Healthcare LLC

GlaxoSmithKline Plc.

Fisher & Paykel Healthcare Limited

Pfizer Inc.

Narcolepsy Treatment Market Segmentation

By Product:

In terms of products, the industry is bifurcated into narcolepsy treatment drugs (Modafinil, Sodium Oxybate, Armodafinil, and others) and devices (CPAP devices, BiPAP devices, and APAP devices)

By Distribution Channel:

In terms of distribution channel, the industry is segregated into hospital pharmacies, retail pharmacies, e-commerce, drug stores, and others.

By Region:

Key countries of North America, Latin America, Western Europe, Eastern Europe, South Asia and Pacific, East Asia, the Middle East, and Africa have been covered in the report.

Explore FMI's Related Ongoing Coverage on Healthcare Market Insights Domain:

In a recently updated edition, trends suggest a valuation of USD 1,583.20 million for the [wearable sleep tracker market size](#) in 2024. The soaring occurrence of sleep dysfunctions is a key catalyst for wearable sleep tracker market growth.

The [global sleep apnea diagnostic systems market share](#) has reached a valuation of USD 4.81 billion in 2023, with a projected CAGR of 6.8% from 2023 to 2033. By 2033, the market is anticipated to reach USD 9.27 billion.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors

that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Join us as we commemorate 10 years of delivering trusted market insights. Reflecting on a decade of achievements, we continue to lead with integrity, innovation, and expertise.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: <https://www.futuremarketinsights.com>

Ankush Nikam
Future Market Insights, Inc.
+91 90966 84197
[email us here](#)
Visit us on social media:
[Facebook](#)
[X](#)
[LinkedIn](#)
[YouTube](#)
[Other](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/776886159>
EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.